Grants for Independent school districts - Federal

This funding opportunity supports researchers in exploring and validating the biological mechanisms linking HIV, substance use disorders, and opioid exposure at a single-cell level, with a focus on data mining existing datasets and conducting functional validation studies.

This grant provides funding for researchers to develop and test innovative behavioral treatments for individuals struggling with drug and alcohol misuse, particularly focusing on improving treatment effectiveness and accessibility for diverse populations.

This program will help rural hospitals expand their services to meet community health needs while increasing their revenues. The program will achieve these goals by providing expert technical assistance to rural hospitals to conduct market assessments, determine ways to enhance existing service lines, and start new service lines to keep services locally. The program will also provide direct financial support to help with associate costs of service lines. This program will also have the affect of helping facilities address long-standing rural disparities.

This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

This grant provides funding to nonprofit organizations and government entities to deliver essential family planning and reproductive health services to low-income and underserved populations across the United States.

This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (see RFA-HL-22-011).

The Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required) aims to support licensed neurologists and neurosurgeons in the NINDS intramural program as they transition to independent academic positions while leading clinical trials and advancing their research careers in neuroscience.

This funding opportunity supports research projects that investigate the long-term impacts of disasters on healthcare systems serving vulnerable populations in the U.S., aiming to improve access and reduce health disparities.

This funding opportunity supports U.S.-based small businesses in the clinical validation of biomarkers for neurological or neuromuscular disorders, promoting inclusivity and collaboration while ensuring rigorous scientific standards for potential diagnostic and therapeutic applications.

Reissue of PAR-20-118. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.

This grant provides funding for research studies that explore the relationship between autophagy, HIV infection, and substance use disorders, aiming to uncover mechanisms that could lead to new therapeutic strategies for affected individuals.

This funding opportunity provides resources to support global health initiatives aimed at preventing, detecting, and responding to public health threats in collaboration with health ministries and governmental institutions worldwide.

This funding opportunity provides financial support for research projects that evaluate effective strategies to prevent child sexual abuse and problematic sexual behavior among youth, particularly through community partnerships and addressing health equity.

This funding opportunity supports educational programs that provide research experiences for undergraduate students from diverse backgrounds to encourage their pursuit of careers in aging-related research.

The National Cancer Institute (NCI) intends to issue a notice of funding opportunity (NOFO) for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialists Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigator of research project grants. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. Applications are limited to four per institution per receipt date including new (A0) and resubmissions (A1). NCI-designated cancer center consortia are considered one institution. NCI seeks a broad representation of institutions for this award mechanism and may take this into account when making funding decisions. The NOFO is expected to be published in late summer 2024 with only one expected application due date of November 5, 2024.

This grant provides funding for research projects that explore how climate change affects cancer risks and care, particularly focusing on vulnerable populations and aiming to reduce health disparities.

This funding opportunity supports research that investigates how sex and gender differences impact health outcomes and disease management, targeting a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity supports a variety of organizations in developing and testing new clinical applications derived from basic research to improve health outcomes for individuals with communication disorders.

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

The National Institute on Alcohol Abuse and Alcoholism ( NIAAA) intends to reissue RFA-AA-23-001, Specialized Alcohol Research Centers (P50, Clinical Trial Optional), by publishing a NOFO to solicit applications for a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol-related problems, and other health-related consequences across the lifespan. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Fall 2024. This NOFO will utilize the P50 activity code. Details of the planned NOFO are provided below.